Format

Send to

Choose Destination
Int J Hematol. 2019 Jan;109(1):41-49. doi: 10.1007/s12185-018-2501-8. Epub 2018 Jul 23.

Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.

Author information

1
Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, Hokkaido, 078-8510, Japan. ikuta@asahikawa-med.ac.jp.
2
New Medical Research System Clinic, Tokyo, Japan.
3
Minamimorimachi Ladies' Clinic, Osaka, Japan.
4
Department of Gynecology, Kurashiki Medical Center, Okayama, Japan.
5
Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
6
Clinical Research 2, Zeria Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan.
7
Department of Integrated Women's Health, St. Luke's International Hospital, Tokyo, Japan.

Abstract

The intravenous formulation for supplementing iron currently available in Japan requires frequent administration. In contrast, ferric carboxymaltose (FCM) can improve iron-deficiency anemia (IDA) with only a small number of administrations; however, its efficacy and safety have not been established in Japanese patients. In this randomized, open-label study, we verified the noninferiority of FCM to saccharated ferric oxide (SFO) in Japanese patients with IDA due to hypermenorrhea, with the mean change from baseline to the highest observed hemoglobin level as the primary endpoint. Two hundred and thirty-eight eligible subjects (119 in FCM group, 119 in SFO group) were administered the investigational medicinal product and included in the analysis. The adjusted mean change from baseline to the highest observed hemoglobin level (95% CI) was 3.90 g/dL (3.77, 4.04) in the FCM group and 4.05 g/dL (3.92, 4.19) in the SFO group, and the difference between the groups (95% CI) was - 0.15 g/dL (- 0.35, 0.04). The noninferiority of FCM was verified. Incidence of adverse events was < 60% in both groups, and no significant difference was observed between the treatment groups. These results indicate that FCM can be a new, well-tolerated, and rapid treatment option for Japanese patients with IDA.

KEYWORDS:

Ferric carboxymaltose (FCM); Hypermenorrhea; Intravenous iron; Iron-deficiency anemia (IDA); Japan

PMID:
30039442
DOI:
10.1007/s12185-018-2501-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center